Bausch Health Companies Inc traded at 8.80 this Wednesday August 5th, decreasing 0.27 or 2.98 percent since the previous trading session. Looking back, over the last four weeks, Bausch Health Companies lost 28.84 percent. Over the last 12 months, its price rose by 11.11 percent. Looking ahead, we forecast Bausch Health Companies Inc to be priced at 9.44 by the end of this quarter and at 8.82 in one year, according to Trading Economics global macro models projections and analysts expectations.
Bausch Health Companies Inc, formerly Valeant Pharmaceuticals International Inc, is a Canada-based company that develops, manufactures and markets a range of branded and generic pharmaceuticals, medical devices and over-the-counter products. It primarily develops products in the therapeutic areas of eye health, gastroenterology and dermatology. Its dermatology products treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis and other dermatoses. It also offers a selection of aesthetic medical devices that address a variety of conditions, including facial wrinkles, acne, pigmentation conditions and laser hair removal, among others. The gastrointestinal (GI) segment offers products that treat GI and hepatologic conditions, including hepatic encephalopathy, irritable bowel syndrome with diarrhea and ulcerative colitis, among others. Its eye health products are marketed in the following categories: Contact Lens, Pharmaceutical Products and Surgical.